Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Optimising treatment of CF pulmonary exacerbation: a tough nut to crack.

Literature DB >> 26769012

Optimising treatment of CF pulmonary exacerbation: a tough nut to crack.

Sonya L Heltshe¹, Christopher H Goss².

Abstract

Entities: Chemical

Keywords: Bronchiectasis; Cystic Fibrosis

Mesh：

Substances：

Year: 2016 PMID： 26769012 PMCID： PMC5476924 DOI： 10.1136/thoraxjnl-2015-208057

Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.102

Keyword Cloud
References

× No keyword cloud information.

19 in total

1. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.

Authors: Iara Maria Sequeiros; Nabil Jarad
Journal: Chron Respir Dis Date: 2012-02 Impact factor: 2.444

2. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.

Authors: Maria T Britto; Uma R Kotagal; Richard W Hornung; Harry D Atherton; Joel Tsevat; Robert W Wilmott
Journal: Chest Date: 2002-01 Impact factor: 9.410

3. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.

Authors: Yvonne C W Yau; Felix Ratjen; Elizabeth Tullis; Pearce Wilcox; Andreas Freitag; Mark Chilvers; Hartmut Grasemann; James Zlosnik; David Speert; Mary Corey; Sanja Stanojevic; Larissa Matukas; Timothy Ronan Leahy; Sarah Shih; Valerie Waters
Journal: J Cyst Fibros Date: 2014-10-30 Impact factor: 5.482

4. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis.

Authors: A L Smith; C Doershuk; D Goldmann; E Gore; B Hilman; M Marks; R Moss; B Ramsey; G Redding; T Rubio; J Williams-Warren; R Wilmott; H D Wilson; R Yogev
Journal: J Pediatr Date: 1999-04 Impact factor: 4.406

5. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.

Authors: Kaïssa de Boer; Katherine L Vandemheen; Elizabeth Tullis; Steve Doucette; Dean Fergusson; Andreas Freitag; Nigel Paterson; Mary Jackson; M Diane Lougheed; Vijay Kumar; Shawn D Aaron
Journal: Thorax Date: 2011-06-15 Impact factor: 9.139

6. Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial.

Authors: Tiffany J Dwyer; Lisel Robbins; Patrick Kelly; Amanda J Piper; Scott C Bell; Peter T P Bye
Journal: J Physiother Date: 2015-06-18 Impact factor: 7.000

Optimising treatment of CF pulmonary exacerbation: a tough nut to crack.

1. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.

2. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.

3. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.

4. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis.

5. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.

6. Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial.

7. Patient-reported respiratory symptoms in cystic fibrosis.

8. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.

Review 9. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

Review 10. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.